Notably, prior exposure to dupilumab did not affect treatment response, and both upadacitinib doses demonstrated comparable efficacy, although the 30 mg dose showed a trend toward greater pruritus reduction at week 16 [ 23 ].
← all excerpts
The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence.
1
—
—